PL438737A1 - Hybrydy GO-2-ME i rGO 2-ME, sposób ich otrzymywania oraz zastosowanie - Google Patents

Hybrydy GO-2-ME i rGO 2-ME, sposób ich otrzymywania oraz zastosowanie Download PDF

Info

Publication number
PL438737A1
PL438737A1 PL438737A PL43873721A PL438737A1 PL 438737 A1 PL438737 A1 PL 438737A1 PL 438737 A PL438737 A PL 438737A PL 43873721 A PL43873721 A PL 43873721A PL 438737 A1 PL438737 A1 PL 438737A1
Authority
PL
Poland
Prior art keywords
rgo
hybrids
preparation
application
graphene oxide
Prior art date
Application number
PL438737A
Other languages
English (en)
Other versions
PL243445B1 (pl
Inventor
Magdalena Górska-Ponikowska
Ludwika LIPIŃSKA
Joanna Gierałtowska
Magdalena Baran
Adrian CHLANDA
Krystian Kowiorski
Lucyna KONIECZNA
Mariusz BELKA
Anna KAMM
Alicja KUBAN-JANKOWSKA
Jacek Gulczyński
Ewa Iżycka-Świeszewska
Narcyz KNAP
Aleksander Żołnierski
Tomasz BĄCZEK
Original Assignee
Gdański Uniwersytet Medyczny
Sieć Badawcza Łukasiewicz - Instytut Mikroelektroniki I Fotoniki
Instytut Nauk Ekonomicznych Państwowej Akademii Nauk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gdański Uniwersytet Medyczny, Sieć Badawcza Łukasiewicz - Instytut Mikroelektroniki I Fotoniki, Instytut Nauk Ekonomicznych Państwowej Akademii Nauk filed Critical Gdański Uniwersytet Medyczny
Priority to PL438737A priority Critical patent/PL243445B1/pl
Priority to EP22856321.9A priority patent/EP4384222A1/en
Priority to PCT/PL2022/050050 priority patent/WO2023018342A1/en
Publication of PL438737A1 publication Critical patent/PL438737A1/pl
Publication of PL243445B1 publication Critical patent/PL243445B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Ceramic Engineering (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Wynalazek dotyczy hybryd GO-2-ME2 lub rGO-2-ME stanowiących stabilne połączenie cząsteczek 2-metoksyestradiolu (2-ME) z tlenkiem grafenu GO lub zredukowanym tlenkiem grafenu rGO, sposobu ich wytwarzania oraz zastosowania jako leku przeciwnowotworowego.
PL438737A 2021-08-13 2021-08-13 Hybrydy GO-2-ME i rGO 2-ME, sposób ich otrzymywania oraz zastosowanie PL243445B1 (pl)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL438737A PL243445B1 (pl) 2021-08-13 2021-08-13 Hybrydy GO-2-ME i rGO 2-ME, sposób ich otrzymywania oraz zastosowanie
EP22856321.9A EP4384222A1 (en) 2021-08-13 2022-08-12 Go-2-me and rgo 2-me hybrids, the method of obtaining them, and their application
PCT/PL2022/050050 WO2023018342A1 (en) 2021-08-13 2022-08-12 Go-2-me and rgo 2-me hybrids, the method of obtaining them, and their application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL438737A PL243445B1 (pl) 2021-08-13 2021-08-13 Hybrydy GO-2-ME i rGO 2-ME, sposób ich otrzymywania oraz zastosowanie

Publications (2)

Publication Number Publication Date
PL438737A1 true PL438737A1 (pl) 2023-02-20
PL243445B1 PL243445B1 (pl) 2023-08-28

Family

ID=85200946

Family Applications (1)

Application Number Title Priority Date Filing Date
PL438737A PL243445B1 (pl) 2021-08-13 2021-08-13 Hybrydy GO-2-ME i rGO 2-ME, sposób ich otrzymywania oraz zastosowanie

Country Status (3)

Country Link
EP (1) EP4384222A1 (pl)
PL (1) PL243445B1 (pl)
WO (1) WO2023018342A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL449413A1 (pl) * 2024-07-30 2026-02-02 Gdański Uniwersytet Medyczny Kompozycja farmaceutyczna, preparat zawierający kompozycję farmaceutyczną i ich zastosowanie w leczeniu nowotworów skóry
PL450037A1 (pl) * 2024-10-15 2026-04-20 Wojskowa Akademia Techniczna Im. Jarosława Dąbrowskiego Zawiesina tlenku grafenu do podawania w postaci aerozolu i jej zastosowanie

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2532449A (en) * 2014-11-19 2016-05-25 Univ Manchester Use of Nanomaterials in treating cancer

Also Published As

Publication number Publication date
PL243445B1 (pl) 2023-08-28
WO2023018342A1 (en) 2023-02-16
EP4384222A1 (en) 2024-06-19

Similar Documents

Publication Publication Date Title
CO2021005987A2 (es) Compuestos de anillo fusionado
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
CL2018000829A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
JOP20200110A1 (ar) متبلورات مضادة جديدة لسلسلة من مركبات مضادة للفيروسات
CL2021002503A1 (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos. (divisional de solicitud 201902251)
UY36175A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
CY1124809T1 (el) Διαστεροεπιλεκτικη συνθεση φωσφορικων παραγωγων και προφαρμακου γεμσιταβινης nuc-1031
MX2017006536A (es) Derivados de piridincarboxamida, su metodo de preparacion y sus usos farmaceuticos.
EA202090014A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
UY36737A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
BR112017025711A2 (pt) ?composições, processo para preparação de siloxanos modificados por poliéter e uso das composições inovadoras?
JOP20190262B1 (ar) مثبطات بيرازول magl
EA201890898A1 (ru) Новые соединения и конъюгаты криптофицина, их получение и их терапевтическое применение
GT201700190A (es) Desacetoxitubulisina h y análogos de esta
BR112017009545B8 (pt) Composição antibacteriana farmacêutica ou veterinária e método in vitro para a preparação de uma composição farmacêutica ou veterinária
BR112017018620A2 (pt) método de administração de tradipitanto, e, tradipitanto.
MX2021000773A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos de uso del mismo.
PL438737A1 (pl) Hybrydy GO-2-ME i rGO 2-ME, sposób ich otrzymywania oraz zastosowanie
BR112018010692A8 (pt) composições imunoestimuladoras, usos de melanina ou de um precursor da melanina e método para obter uma composição imunoestimuladora
MX2017015137A (es) Composicion farmaceutica oral de dosis diaria de isotretinoin.
MX374931B (es) Composiciones farmaceuticas que contienen doravirina, tenofovir disoproxil fumarato y lamivudina.
BR112017014189A2 (pt) terapia de câncer com um parvovirus combinado com bevacizumabe
BR112012022090A2 (pt) utilização de ácido elágico como agente anticaspa
BR112017000772A2 (pt) composição para formar um briquete de carepa de laminação, e briquete de carepa de laminação